Onsdag 30 Oktober | 09:26:53 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-14 11:30 Bokslutskommuniké 2024
2024-11-08 09:00 Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning COMBI 0.00 SEK
2024-05-23 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning COMBI 0.00 SEK
2023-05-25 - Årsstämma
2023-05-12 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning COMBI 0.00 SEK
2022-05-19 - Årsstämma
2022-05-12 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-12 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-06-07 - Split COMBI 20:1
2021-05-26 - X-dag ordinarie utdelning COMBI 0.00 SEK
2021-05-25 - Årsstämma
2021-05-12 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-13 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-06-30 - X-dag ordinarie utdelning COMBI 0.00 SEK
2020-06-29 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-05-17 - Kvartalsrapport 2019-Q1
2019-05-16 - Årsstämma
2019-05-15 - X-dag ordinarie utdelning COMBI 0.00 SEK
2019-02-14 - Bokslutskommuniké 2018
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-04 - X-dag ordinarie utdelning COMBI 0.00 SEK
2018-05-03 - Kvartalsrapport 2018-Q1
2018-05-03 - Årsstämma
2018-01-29 - Bokslutskommuniké 2017
2017-11-01 - Kvartalsrapport 2017-Q3
2017-08-17 - Kvartalsrapport 2017-Q2
2017-05-18 - Kvartalsrapport 2017-Q1
2017-05-10 - X-dag ordinarie utdelning COMBI 0.00 SEK
2017-05-09 - Årsstämma
2017-01-31 - Bokslutskommuniké 2016
2017-01-26 - Extra Bolagsstämma 2017
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-19 - Kvartalsrapport 2016-Q1
2016-04-05 - X-dag ordinarie utdelning COMBI 0.00 SEK
2016-04-04 - Årsstämma
2016-02-18 - Bokslutskommuniké 2015
2015-11-19 - Kvartalsrapport 2015-Q3
2015-08-20 - Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
CombiGenes vision är att ge patienter som drabbats av svåra sjukdomar möjlighet till ett bättre liv genom genterapi och andra former av avancerade behandlingar. Bolagets verksamhet har tre fokusområden: inlicensiering av nya tillgångar, utveckling av dessa tillgångar till proof-of-concept samt utlicensiering av tillgångarna till en strategisk partner för fortsatt utveckling och kommersialisering. CombiGene has sitt säte i Stockholm.
2023-12-20 16:45:00

CombiGene AB (publ) ("CombiGene", the "Company") today announces that the peptide-based pain project COZY01 receives Eurostars funding of EUR 726,435, corresponding to approximately SEK 8,7 million. The funding from Eurostars will be used to identify potential biomarkers of effect on the target protein, demonstrate efficacy of the treatment in human tissue, and develop and produce clinical trial material for the first study in humans.

COZY01 is a peptide treatment for severe chronic pain conditions. The project is being co-developed with CombiGene's Danish partner Zyneyro, which is also a partner in the Eurostars application. The treatment has shown good effects in various preclinical models. The continued development includes preclinical studies to evaluate safety and toxicology as well as to produce clinical trial material in order to obtain approval from regulatory authorities to conduct the first clinical trials in humans with COZY01.

The fact that Eurostars, through the national authorities Vinnova in Sweden and the Innovation Fund in Denmark, chooses to invest almost SEK 8 million in our peptide-based pain project COZY01 is extremely gratifying. Projects selected for funding under Eurostars must be innovative and have a clear market orientation. Only about 30% of all applications to Eurostars are successful, which underlines the rigor and selectivity of the selection process. The Eurostars funding thus constitutes a clear stamp of quality for the COZY01 project. The grant from Eurostars will finance key parts of the continued development of COZY01 and also means that the project has received a very important external validation,” comments CombiGene's CEO Peter Ekolind.

About the pain program COZY
The COZY pain program is being developed to offer effective pain relief without the side effects that current treatments often cause. This is possible as Zyneyro’s researchers have identified a new biological mechanism of action that forms the basis for the COZY pain program. The mechanism of action was discovered by Zyneyro’s researchers while they were still at the University of Copenhagen. The program consists of two projects: a peptide treatment (short-term treatment) and a gene therapy treatment with potentially lifelong effect. The patient’s clinical picture and other factors will guide the choice of therapy, COZY01 or COZY02. The program is run jointly by CombiGene and Zyneyro and the project’s costs and future revenues are shared equally between the two companies.

About Zyneyro ApS
Zyneyro was founded by a group of researchers from the Department of Neuroscience at the University of Copenhagen and a group of entrepreneurs who together have extensive experience in all aspects of early drug development and entrepreneurship. The company’s researchers have worked for more than 15 years to understand the ability of the brain and nervous system to adapt to the influence of the surrounding environment. Zyneyro’s goal is to translate this knowledge of modulation of neuronal interaction into developing a number of drug candidates. The drug candidates included in the collaboration with CombiGene relate to the treatment of pain. Zyneyro also intends to develop other drug candidates for indications other than pain.

About Eurostars
Eurostars is part of the European Partnership for Innovative Small and Medium-sized Enterprises (SMEs), which is primarily aimed at innovative SMEs involved in international projects. It is possible to apply for funding for the development of market-oriented processes, products, and services. Through international collaboration, Eurostars provides access to new knowledge, collaborations, and opportunities to test new markets.